You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Medtronic
Baxter
Moodys
Colorcon

Last Updated: April 19, 2021

DrugPatentWatch Database Preview

POTASSIUM CHLORIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Potassium Chloride patents expire, and when can generic versions of Potassium Chloride launch?

Potassium Chloride is a drug marketed by Actavis Labs Fl Inc, Adare Pharms Inc, Amneal Pharms, Anchen Pharms, Glenmark Pharms Ltd, Lannett Co Inc, Lupin Ltd, Nesher Pharms, Novel Labs Inc, Paddock Llc, Prinston Inc, Strides Pharma, Teva, Tris Pharma Inc, Zydus Pharms, Amneal, Belcher, Epic Pharma Llc, Pharma Res Software, Abraxis Pharm, Akorn, B Braun, Baxter Hlthcare, Fresenius Kabi Usa, Gd Searle Llc, Hospira, Intl Medication, Lilly, Luitpold, Miles, Pharma Serve Ny, Watson Labs, Apotex, Genus Lifesciences, Pharm Assoc, Ascent Pharms Inc, Aurobindo Pharma Ltd, Centaur Pharms Pvt, Copley Pharm, Granules, Granules Pharms, Mylan, Paddock Labs Llc, Schering, Sigmapharm Labs Llc, Vitruvias Therap, Yichang Humanwell, and Icu Medical Inc. and is included in one hundred and four NDAs.

The generic ingredient in POTASSIUM CHLORIDE is calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate. There are two hundred and eighty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate profile page.

US Patents and Regulatory Information for POTASSIUM CHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs POTASSIUM CHLORIDE potassium chloride INJECTABLE;INJECTION 089163-001 Mar 10, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
Baxter Hlthcare POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER dextrose; potassium chloride; sodium chloride INJECTABLE;INJECTION 018008-004 Approved Prior to Jan 1, 1982 RX No No   Start Trial   Start Trial   Start Trial
Icu Medical Inc POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER potassium chloride INJECTABLE;INJECTION 020161-005 Nov 30, 1992 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Glenmark Pharms Ltd POTASSIUM CHLORIDE potassium chloride TABLET, EXTENDED RELEASE;ORAL 203562-002 Jul 26, 2016 AB1 RX No No   Start Trial   Start Trial   Start Trial
Icu Medical Inc POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER dextrose; potassium chloride; sodium chloride INJECTABLE;INJECTION 018365-001 Approved Prior to Jan 1, 1982 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for POTASSIUM CHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering POTASSIUM CHLORIDE potassium chloride TABLET, EXTENDED RELEASE;ORAL 019439-002 Jun 13, 1986   Start Trial   Start Trial
Schering POTASSIUM CHLORIDE potassium chloride TABLET, EXTENDED RELEASE;ORAL 019439-001 Jun 13, 1986   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for POTASSIUM CHLORIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1718641 2012/008 Ireland   Start Trial PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
0253310 SPC/GB95/010 United Kingdom   Start Trial PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
1718641 SPC/GB12/028 United Kingdom   Start Trial PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
1499331 SPC/GB13/034 United Kingdom   Start Trial PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
1441735 2008/010 Ireland   Start Trial PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220;
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.